CLAIM CARD
Quantitative findings from real-world and observational cohorts corroborate the mortality signal. In a pooled analysis of real-world evidence, E 2026 demonstrated consistent reductions in heart failure hospitalization (pooled HR 0.65, 95% CI 0.59-0.72), though the direct mortality effect remained unclear with P > 0.05 for all-cause death endpoints. Daniyal 2026 extended these findings to transcatheter aortic valve replacement populations, reporting pooled hazard ratios indicating SGLT2 inhibitor use associated with reduced mortality (P < 0.01, P = 0.03).
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025